Year: 2021
Type: article
Abstract: In this issue of Blood, Rao et al reveal important insights into how hematopoietic stem cell (HSC) subpopulations contribute to myeloproliferative neoplasm (MPN) pathogenesis, and how these populations are perturbed in the setting of pegylated-interferon (pegIFN) therapy. 1
Source: Blood
Authors: Andrew Dunbar, Ross L. Levine
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3156903427